These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36215113)

  • 21. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
    Berger ML
    J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies to Address Current Challenges in Real-World Evidence Generation in Japan.
    Laurent T; Lambrelli D; Wakabayashi R; Hirano T; Kuwatsuru R
    Drugs Real World Outcomes; 2023 Jun; 10(2):167-176. PubMed ID: 37178273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force.
    Fleurence RL; Kent S; Adamson B; Tcheng J; Balicer R; Ross JS; Haynes K; Muller P; Campbell J; Bouée-Benhamiche E; García Martí S; Ramsey S
    Value Health; 2024 Jun; 27(6):692-701. PubMed ID: 38871437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world evidence to support regulatory decision making: New or expanded medical product indications.
    Franklin JM; Liaw KL; Iyasu S; Critchlow CW; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):685-693. PubMed ID: 33675248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting.
    Gatto NM; Wang SV; Murk W; Mattox P; Brookhart MA; Bate A; Schneeweiss S; Rassen JA
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1140-1152. PubMed ID: 35984046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research.
    Wang SV; Pottegård A
    Am J Epidemiol; 2024 Nov; 193(11):1625-1631. PubMed ID: 38794897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 11.
    Bray B; Ramagopalan SV
    J Comp Eff Res; 2023 May; 12(5):e230008. PubMed ID: 37052075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
    Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Canuto Santos V; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
    Value Health; 2022 Jun; 25(6):869-886. PubMed ID: 35667778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
    Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Santos VC; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
    Int J Technol Assess Health Care; 2022 Jun; 38(1):e37. PubMed ID: 35656641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments.
    Schneeweiss S; Patorno E
    Endocr Rev; 2021 Sep; 42(5):658-690. PubMed ID: 33710268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.